News
Regeneron's third-largest drug, Libtayo, remains the standard of care in advanced cutaneous squamous cell carcinoma. However, ...
Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a ...
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results